Neurocrine Biosciences, Inc. (NBIX)

138.97 -1.12 (-0.80%) At close: 04:00PM EDT

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,400

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Kevin C. Gorman Ph.D.	CEO & Director	2.05M	N/A	1958
Mr. Matthew C. Abernethy	Chief Financial Officer	1.06M	N/A	1980
Dr. Jude Onyia Ph.D.	Chief Scientific Officer	1.22M	N/A	1965
Mr. Kyle W. Gano Ph.D.	Chief Business Development & Strategy Officer	990.12k	N/A	1973
Dr. Eiry Wyn Roberts M.D.	Chief Medical Officer	1.12M	4.15M	1965
Jane Sorensen	Head of Investor Relations	N/A	N/A	N/A
Mr. Darin M. Lippoldt Esq.	Chief Legal Officer & Corporate Secretary	921.01k	2.98M	1966
Ms. Julie S. Cooke	Chief Human Resources Officer	N/A	N/A	1966
Mr. Eric S. Benevich	Chief Commercial Officer	805k	295.52k	1965
Mr. David Warren Boyer	Chief Corporate Affairs Officer	N/A	N/A	1980

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Corporate governance

Neurocrine Biosciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.